Svendborg Hospital   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Odense Denmark (1912)

Organization Overview

First Clinical Trial
2008
NCT00643448
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Svendborg Hospital | Svendborg Sygehus, Forsknings-og udviklingsafd.

Active Ingredients

Drugs in Phase 3 Trials (2)

semaglutide (Ozempic) (1 trial)

spironolactone (aldactone) (1 trial)

Drugs in Phase 2 Trials (3)

azd-1305 (1 trial)

rosuvastatin (crestor) (1 trial)

simvastatin (zocor) (1 trial)

Drugs in Other Trials (1)

hydroxyethyl starch (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Fibrosis (Phase 3)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 6